Interní Med. 2015; 17(2): 70-72

Dyslipidemia and metabolic syndrom

prof.MUDr.Vladimír Soška, CSc.

Oddělení klinické biochemie, ICRC a Fakultní nemocnice u sv. Anny, Brno

Katedra laboratorních metod, II. interní klinika, LF MU Brno

Dyslipidemia is one of the main components of the metabolic syndrom. Is is characterized by elevated triglycerides, low HDL-cholesterol

and elevated concentrations of small aterogenic LDL particles. The basic step in treatment should be always a lifestyle changes, especially

changes in diet, weight optimization and ban of smoking. Pharmacotherapy DLP is indicated if a patient is in very high or high risk of

fatal cardiovascular event during next 10 years and if (at the same time) is LDL-cholesterol higher than its target level. Pharmacotherapy

is based on statins therapy, in case of their intolerance ezetimibe. If target level of LDL-cholesterol is achieved and persist elevated levels

of triglycerides and/or decreased HDL-cholesterol, adding fenofibrate to a statin should be considered.

Keywords: dyslipidemia, metabolic syndrom, HDL cholesterol, triglycerides, statins, fenofibrate

Published: April 10, 2015  Show citation